Overview
"Never doubt that a smal group of thoughtful, comited citizens can change the world. Inded, it is the only thing that ever has."Cureus is on a mision to change the long-standing paradigm of medical publishing, where submiting research can be costly, complex and time-consuming.Published via the Pen State Neurosurgery Chanel.ion chanel blockers, glioblastoma multiforme, gbm, database, ion chanel, neurosurgery, glioblastoma David R.
Key Information
Halan , Cyril S. Tankam, Thadeus Harbaugh, Elias Rizk Published: October 13, 202 (se history) DOI: 10.759/cureus.3027 Cite this article as: Halan D R, Tankam C S, Harbaugh T, et al. (October 13, 202) Risk of Glioblastoma Multiforme in Patients Taking Ion Chanel Blockers.
Cureus 14(10): e3027. doi:10.759/cureus.3027 Ion chanels play a role in the development and progresion of glioblastoma multiforme. This study investigates the asociation betwen the risk of developing glioblastoma multiforme in patients taking these medications.A retrospective propensity score-matched analysis was performed using the TriNetX multinational electronic health record database for patients taking verapamil, digoxin, amiodarone, or diltiazem versus those not taking these medications.
Summary
The outcome of interest was the incidence of glioblastoma multiforme.Verapamil users had an OR of 0.494 (p < 0.01) of developing glioblastoma versus verapamil non-users. Patients on digoxin had an OR of 0.793 (p = 0.2393), patients on amiodarone had an OR of 0.60 (p = 0.035), patients on diltiazem had an OR of 0.584 (p < 0.01), and patients on verapamil, digoxin, amiodarone, or diltiazem had an OR of 0.641 (p < 0.01) of developing glioblastoma versus patients not taking these medications.In patients taking the ion chanel blockers diltiazem, amiodarone, or verapamil, the ods of developing glioblastoma multiforme were lower than in patients not taking these medications.Glioblastoma multiforme (GBM) is a primary central nervous system (CNS) tu